Patrassi G M, Martinelli S, Sturniolo G C, Cappellato M G, Vicariotto M, Girolami A
Eur J Clin Invest. 1985 Aug;15(4):161-5. doi: 10.1111/j.1365-2362.1985.tb00162.x.
Management of cirrhosis with massive ascites involves particular difficulties. The introduction of a peritoneovenous shunt and reinfusion of concentrated ascitic fluid techniques allows increased diuresis and improves renal function. However, these procedures have frequently been associated with disseminated intravascular coagulation and/or activation of fibrinolysis. Factor VIII activity, antigen and ristocetin cofactor, plasminogen, antiplasmin, plasminogen activator activity and plasmin-antiplasmin complex were investigated both in the ascitic fluid and plasma of cirrhotic patients before and after the concentration-reinfusion technique. Our results indicated that no hyperfibrinolysis was seen in the plasma of cirrhotic patients and that activation of fibrinolysis exists in ascites. Significantly higher levels of plasmin-antiplasmin complex and plasminogen activator activity were found in ascitic fluid than in plasma. In post-reinfusion much higher levels of all three Factor VIII components were observed in cirrhotic plasma than in normal plasma. In conclusion, activation of fibrinolysis could explain coagulation complications occurring after ascites reinfusion. Antifibrinolytic treatment could render the concentration-reinfusion technique more acceptable.
伴有大量腹水的肝硬化的治疗存在特殊困难。采用腹腔静脉分流术和浓缩腹水回输技术可增加利尿并改善肾功能。然而,这些操作常常与弥散性血管内凝血和/或纤维蛋白溶解激活有关。对肝硬化患者在浓缩回输技术前后的腹水和血浆中的Ⅷ因子活性、抗原和瑞斯托菌素辅因子、纤溶酶原、抗纤溶酶、纤溶酶原激活物活性及纤溶酶 - 抗纤溶酶复合物进行了研究。我们的结果表明,肝硬化患者血浆中未见高纤溶状态,而腹水中存在纤维蛋白溶解激活。腹水中纤溶酶 - 抗纤溶酶复合物和纤溶酶原激活物活性水平显著高于血浆。回输后,肝硬化患者血浆中所有三种Ⅷ因子成分的水平均显著高于正常血浆。总之,纤维蛋白溶解激活可解释腹水回输后发生的凝血并发症。抗纤溶治疗可能会使浓缩回输技术更易被接受。